Trial reportThe American journal of medicine2014
Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease.
Trial report in The American journal of medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.The Cochrane database of systematic reviews · 2026Pooled it
- What is the effectiveness of surgical and non-surgical therapies in the treatment of ischemic priapism in patients with sickle cell disease? A systematic review by the EAU Sexual and Reproductive Health Guidelines Panel.International journal of impotence research · 2024Pooled it
- Treatments for priapism in boys and men with sickle cell disease.The Cochrane database of systematic reviews · 2020Pooled it
- Treatments for priapism in boys and men with sickle cell disease.The Cochrane database of systematic reviews · 2017Pooled it
- Current evidence on the management of ischaemic priapism post-shunting: a narrative review.International journal of impotence research · 2026Review
- Sympathetic hypoactivity leads to hypocontractility of the corpus cavernosum in sickle cell mice: a mechanism contributing to priapism.International journal of impotence research · 2026Article
- Review
- An update on mechanisms and treatment options for priapism.Nature reviews. Urology · 2025Review
- Resveratrol attenuates the priapism phenotype in sickle cell mice by restoring NO-cGMP-PDE5 signaling and reducing NADPH oxidase 2 expression.Frontiers in pharmacology · 2025Article
- Idiopathic recurrent ischemic priapism: a review of current literature and an algorithmic approach to evaluation and management.Basic and clinical andrology · 2024Article
- Epidemiology and treatment of priapism in sickle cell disease.Hematology. American Society of Hematology. Education Program · 2022Review
- Rare emergency in children: Priapism and stepwise treatment approach.Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2022Article
- Using cyproterone acetate to treat recurrent ischemic priapism in a patient with sickle cell anemia as a comorbidity: a case report.Journal of medical case reports · 2020Article
- Prevalence of priapism in individuals with sickle cell disease and implications on male sexual function.Einstein (Sao Paulo, Brazil) · 2020Article
- cGMP modulation therapeutics for sickle cell disease.Experimental biology and medicine (Maywood, N.J.) · 2019Review
- THE SCIENCE AND PRACTICE OF ERECTION PHYSIOLOGY: STORY OF A REVOLUTIONARY GASEOUS MOLECULE.Transactions of the American Clinical and Climatological Association · 2019Review
- Molecular Profile of Priapism Associated with Low Nitric Oxide Bioavailability.Journal of proteome research · 2018Article
- Advances in the understanding of priapism.Translational andrology and urology · 2017Review
- [Side effects of erectile dysfunction drug treatment].Der Urologe. Ausg. A · 2017Article
- Pediatric sickle cell disease: past successes and future challenges.Pediatric research · 2017Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundSuccessful preventive therapy for ischemic priapism, a disorder of penile erection with major physical and psychologic consequences, is limited. We conducted a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of sildenafil by a systematic dosing protocol to prevent recurrent ischemic priapism associated with sickle cell disease.
methodsThirteen patients with sickle cell disease reporting priapism recurrences at least twice weekly were randomized to receive sildenafil 50 mg or placebo daily, unassociated with sleep or sexual activity, for 8 weeks, followed by open-label use of this sildenafil regimen for an additional 8 weeks.
resultsPriapism frequency reduction by 50% did not differ between sildenafil and placebo groups by intention-to-treat or per protocol analyses (P = 1.0). However, during open-label assessment, 5 of 8 patients (62.5%) by intention-to-treat analysis and 2 of 3 patients (66.7%) by per protocol analysis met this primary efficacy outcome. No significant differences were found between study groups in rates of adverse effects, although major priapism episodes were decreased 4-fold in patients monitored "on-treatment."
conclusionsSildenafil use by systematic dosing may offer a strategy to prevent recurrent ischemic priapism in patients with sickle cell disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.